8-K: Century Therapeutics Reports Full Year 2023 Results and Provides Business Update, Highlighting Progress in Cell Therapy Development

Century Therapeutics announced its full year 2023 financial results and provided a business update, showcasing promising initial data from its Phase 1 ELiPSE-1 trial and progress in its iPSC-derived cell therapy platform.

Summary

• Century Therapeutics reported its full year 2023 financial results, including a net loss of $136.7 million, compared to a net loss of $131.0 million in 2022.
• The company's cash, cash equivalents, and investments totaled $261.8 million as of December 31, 2023, down from $367.4 million the previous year.
• Research and development expenses were $92.7 million for 2023, a decrease from $97.2 million in 2022, due to a reorganization and reprioritization of early-stage programs.
• General and administrative expenses increased to $34.7 million in 2023 from $31.9 million in 2022, primarily due to stock-based compensation and recruiting fees.
• A one-time impairment charge of $16.4 million was recorded due to the consolidation of leased facilities.
• The company presented initial data from the Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory B-cell lymphomas, showing a favorable tolerability profile and early clinical activity.
• Century received IND clearance for CNTY-101 for the treatment of systemic lupus erythematosus (SLE) and plans to initiate a Phase 1 clinical trial in the first half of 2024.
• Six posters will be presented at the upcoming AACR Annual Meeting 2024, highlighting the company's cell therapy capabilities.
• The company expects full year GAAP operating expenses to be between $135 million and $145 million and estimates its cash will support operations into 2026.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical data and a clear path forward, but also acknowledges financial losses and risks inherent in drug development. The positive clinical results and expansion into autoimmune indications are encouraging, but the financial situation and risks temper the overall sentiment.

Positives

• The initial clinical data for CNTY-101 shows a favorable safety profile and encouraging early efficacy signals in treating relapsed/refractory B-cell lymphomas.
• The Allo-Evasion technology appears to support a multi-dosing regimen without the need for continued lymphodepletion, which could be a significant advantage.
• The IND clearance for CNTY-101 in SLE expands the potential application of the therapy into autoimmune diseases.
• The company's cash runway extends into 2026, providing financial stability for ongoing research and development.
• The company has a diversified pipeline of product candidates spanning cell platforms and targets in solid and hematologic cancers and autoimmune and inflammatory diseases.
• The company has established in-house manufacturing capabilities, which accelerates learnings and enables faster product iteration.

Negatives

• The company reported a net loss of $136.7 million for 2023, which is an increase from the $131.0 million loss in 2022.
• The company's cash position decreased from $367.4 million at the end of 2022 to $261.8 million at the end of 2023.
• Net cash used in operations was $88.3 million for the twelve months ended December 31, 2023, compared to net cash provided by operations of $14.1 million for the twelve months ended December 31, 2022.
• Collaboration revenue decreased from $5.2 million in 2022 to $2.2 million in 2023.
• A one-time impairment charge of $16.4 million was recorded in connection with the strategic decision to consolidate leased facilities.

Risks

• The company's ability to successfully advance its product candidates through clinical trials is subject to risks and uncertainties.
• The success of the company is heavily dependent on the success of its lead product candidate, CNTY-101.
• The results of preliminary data and earlier-stage clinical trials may not be predictive of final results or the results of later-stage clinical trials.
• The company relies on key collaborative relationships for the manufacturing and development of its product candidates.
• The company's ability to obtain regulatory approvals for its product candidates is not guaranteed.
• Geopolitical issues, banking instability, and inflation could impact the company's business and operations.
• The company faces risks related to the performance of third parties involved in the development of its product candidates.
• The company's ability to successfully commercialize its product candidates and develop sales and marketing capabilities is uncertain.

Future Outlook

The company expects its cash, cash equivalents, and investments will support operations into 2026 and anticipates advancing its clinical programs, including the Phase 1 trial of CNTY-101 in SLE, with initial data expected by year-end 2024.

Management Comments

• Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, stated that the company enters 2024 following a series of significant milestones, highlighted by the presentation at ASH showcasing promising initial data from the ELiPSE-1 trial of CNTY-101.
• He also noted that the early success of the Allo-Evasion technology bolsters confidence in its potential for prolonged and tighter control over drug exposure as the company expands into autoimmune indications.

Industry Context

This announcement is relevant to the broader cell therapy industry, particularly in the development of allogeneic iPSC-derived therapies. The progress of Century's Allo-Evasion technology and its application in both oncology and autoimmune diseases positions the company as a key player in the next generation of cell therapies.

Comparison to Industry Standards

• Century's approach to allogeneic cell therapy using iPSC-derived cells with multiple gene edits is comparable to other companies in the space, such as Fate Therapeutics and Allogene Therapeutics, but with a focus on Allo-Evasion technology to enable repeat dosing without lymphodepletion.
• The initial clinical data from the ELiPSE-1 trial, showing a 6-month durable complete response in one patient, is competitive with early results from other CAR-T and CAR-NK therapies in relapsed/refractory B-cell lymphomas.
• The expansion into autoimmune indications with the IND clearance for CNTY-101 in SLE is a strategic move, as other companies like Kyverna Therapeutics are also exploring CAR-T therapies for autoimmune diseases.
• The company's in-house manufacturing capabilities are similar to other advanced cell therapy companies, allowing for greater control over product quality and supply chain.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical data and the company's cash runway into 2026, but also concerned about the net loss and decrease in cash position.
• Employees may be motivated by the progress in clinical trials and the company's expansion into new therapeutic areas.
• Patients with relapsed/refractory B-cell lymphomas and SLE may benefit from the development of new treatment options.
• Suppliers and collaborators may see opportunities for continued partnerships with the company.

Next Steps

• Initiate the Phase 1 CALiPSO-1 clinical trial for CNTY-101 in SLE in the first half of 2024.
• Present six posters at the AACR Annual Meeting in April 2024.
• Continue enrollment in the ELiPSE-1 trial and advance to higher doses.
• Share additional clinical data from the ELiPSE-1 trial in mid-2024.
• Report initial data from the CALiPSO-1 trial by year-end 2024.

Key Dates

Keywords

iPSC, cell therapy, allogeneic, CNTY-101, Allo-Evasion, lymphoma, systemic lupus erythematosus, autoimmune, immuno-oncology, clinical trial, gene editing, NK cells, CAR-T, FDA, biotechnology